A Deep Look Into the Future of Quantitative Imaging in Oncology

Citation for published version (APA):

Morin, O., Vallieres, M., Jochems, A., Woodruff, H. C., Valdes, G., Braunstein, S. E., Wildberger, J. E., Villanueva-Meyer, J. E., Kearney, V., Yom, S. S., Solberg, T. D., & Lambin, P. (2018). A Deep Look Into the Future of Quantitative Imaging in Oncology: A Statement of Working Principles and Proposal for Change. *International Journal of Radiation Oncology Biology Physics*, 102(4), 1074-1082. <https://doi.org/10.1016/j.ijrobp.2018.08.032>

Document status and date:

Published: 15/11/2018

DOI:

[10.1016/j.ijrobp.2018.08.032](https://doi.org/10.1016/j.ijrobp.2018.08.032)

Document Version:

Publisher's PDF, also known as Version of record

Document license:

Taverne

Please check the document version of this publication:

- A submitted manuscript is the version of the article upon submission and before peer-review. There can be important differences between the submitted version and the official published version of record. People interested in the research are advised to contact the author for the final version of the publication, or visit the DOI to the publisher's website.
- The final author version and the galley proof are versions of the publication after peer review.
- The final published version features the final layout of the paper including the volume, issue and page numbers.

[Link to publication](#)

General rights

Copyright and moral rights for the publications made accessible in the public portal are retained by the authors and/or other copyright owners and it is a condition of accessing publications that users recognise and abide by the legal requirements associated with these rights.

- Users may download and print one copy of any publication from the public portal for the purpose of private study or research.
- You may not further distribute the material or use it for any profit-making activity or commercial gain
- You may freely distribute the URL identifying the publication in the public portal.

If the publication is distributed under the terms of Article 25fa of the Dutch Copyright Act, indicated by the "Taverne" license above, please follow below link for the End User Agreement:

www.umlib.nl/taverne-license

Take down policy

If you believe that this document breaches copyright please contact us at:

repository@maastrichtuniversity.nl

providing details and we will investigate your claim.

Critical Review

A Deep Look Into the Future of Quantitative Imaging in Oncology: A Statement of Working Principles and Proposal for Change

Olivier Morin, PhD,^{*} Martin Vallières, PhD,[†] Arthur Jochems, PhD,[‡]
Henry C. Woodruff, PhD,[‡] Gilmer Valdes, PhD,^{*}
Steve E. Braunstein, MD, PhD,^{*} Joachim E. Wildberger, MD,[§]
Javier E. Villanueva-Meyer, MD,^{||} Vasant Kearney, PhD,^{*}
Sue S. Yom, MD,^{*} Timothy D. Solberg, PhD,^{*} and Philippe Lambin, MD[‡]

^{*}Department of Radiation Oncology, University of California San Francisco, San Francisco, California; [†]Medical Physics Unit, McGill University, Montreal, Canada; [‡]The D-Lab, Grow Research Institute for Oncology, Maastricht University, Maastricht, The Netherlands; [§]Department of Radiology and Nuclear Medicine, Maastricht University Medical Center, Maastricht, The Netherlands; ^{||}Department of Radiology, University of California San Francisco, San Francisco, California

Received Apr 27, 2018, and in revised form Aug 21, 2018. Accepted for publication Aug 21, 2018.

The adoption of enterprise digital imaging, along with the development of quantitative imaging methods and the re-emergence of statistical learning, has opened the opportunity for more personalized cancer treatments through transformative data science research. In the last 5 years, accumulating evidence has indicated that noninvasive advanced imaging analytics (i.e., radiomics) can reveal key components of tumor phenotype for multiple lesions at multiple time points over the course of treatment. Many groups using homegrown software have extracted engineered and deep quantitative features on 3-dimensional medical images for better spatial and longitudinal understanding of tumor biology and for the prediction of diverse outcomes. These developments could augment patient stratification and prognostication, buttressing emerging targeted therapeutic approaches. Unfortunately, the rapid growth in popularity of this immature scientific discipline has resulted in many early publications that miss key information or use underpowered patient data sets, without production of generalizable results. Quantitative imaging research is complex, and key principles should be followed to realize its full potential. The fields of quantitative imaging and radiomics in particular require a renewed focus on optimal study design and reporting practices, standardization, interpretability, data sharing, and clinical trials. Standardization of image acquisition, feature calculation, and statistical analysis (i.e., machine learning) are required for the

Reprint requests to: Olivier Morin, PhD, University of California San Francisco, Radiation Oncology, 505 Parnassus Ave, San Francisco, CA 94143. Tel: 415-353-9302; E-mail: olivier.morin@ucsf.edu

Conflict of interest: P.L. reports grants/sponsored research agreements from Varian medical, Oncoradiomics, ptTheragnostic and outside the submitted work, from Health Innovation Ventures, DualTpharma and ptTheragnostic. He received an advisor (SAB)/presenter fee and/or reimbursement of travel costs/external grant writing fee and/or in kind manpower contribution from Oncoradiomics and, outside the submitted work, BHV and Convert pharmaceuticals.

Dr Lambin has shares in the company Oncoradiomics and, outside the submitted work, Convert pharmaceuticals and is co-inventor of two patents on radiomics (PCT/NL2014/050248, PCT/NL2014/050728) licensed to Oncoradiomics and outside the submitted work, one patent on mtDNA (PCT/EP2014/059089) licensed to ptTheragnostic/DNAmito, three non-patentable invention (softwares), licensed to ptTheragnostic/DNAmito, Oncoradiomics and Health Innovation Ventures. O.M. reports grants from DHART SPOR NCI and is a shareholder of Oncoradiomics. H.C.W. reports other support from Oncoradiomics, and is a funder-shareholder.

field to move forward. A new data-sharing paradigm enacted among open and diverse participants (medical institutions, vendors and associations) should be embraced for faster development and comprehensive clinical validation of imaging biomarkers. In this review and critique of the field, we propose working principles and fundamental changes to the current scientific approach, with the goal of high-impact research and development of actionable prediction models that will yield more meaningful applications of precision cancer medicine. © 2018 Published by Elsevier Inc.

The Birth of a New Scientific Discipline

The role of medical imaging in oncology has expanded considerably since the introduction of computed tomography in the 1970s. The addition of magnetic resonance imaging and of positron emission tomography shortly thereafter brought forth a new level of soft-tissue representation and improved understanding of molecular physiology. In subsequent years, interdisciplinary teams of radiologists, oncologists, and radiation oncologists developed a common radiographic language to document and communicate diagnosis and response to therapy. For the most part, these imaging examinations were

summarized in nonstructured qualitative or semi-quantitative reports focused on the affected organs and the tumor environment. Recently, however, the transition to enterprise digital imaging and re-emergence of statistical learning algorithms (i.e., machine learning) have led to the development of many quantitative imaging models aimed at assisting and augmenting physician decision-making.

The term “radiomics” was introduced in 2012 as the scientific discipline of advanced imaging analysis in medicine. The fundamental hypothesis of radiomics is that microscopic heterogeneity associated with tumor and cellular biology and molecular markers can be captured in the macroscopic heterogeneity of quantitative features

Fig. 1. Top: Opportunities for the development of radiomics prediction models and better risk stratification of patients from a point-of-care perspective. Tumor control, treatment toxicities, and overall survival have all been studied as possible outcomes of the radiomics prediction models. Models developed at the point of diagnosis may be more useful and actionable compared with models past the point of therapy. Delta-radiomics models refer to quantification of changes after therapy or drug delivery. Bottom: Change of oncology treatment paradigm being proposed by the field of quantitative imaging and radiomics. The radiomics model is being proposed as noninvasive biomarkers. The current model relies on limited sampling of the tissue for tumor phenotyping and treatment decision. Radiomics may offer advantages in capturing important 3-dimensional tumor heterogeneity and changes that occur over time.

computed on medical images (1-3). Several radiomics applications have recently emerged, ranging from tumor classification and phenotyping (4-7) to modeling of locoregional control (8) and prognostication of future outcomes (9). Specific quantitative imaging modeling studies were performed on a comprehensive list of tumor sites, including head and neck, (4, 8-13) lung, (3, 4, 14-18) breast, (19-29) liver, (30, 31) cervix, (32-36) prostate, (37, 38) extremities (sarcoma), (39, 40) and brain. (7, 41-54) Figure 1 illustrates the many opportunities offered by radiomics prediction models for improved risk stratification of patients from a point-of-care perspective. Outcome prediction models using clinical and imaging variables could be created to calibrate or adjust treatment strategies using combinations of surgery, radiation therapy, and systemic/targeted drug delivery. Response to therapies, including novel pharmaceutical agents, could be adaptively modeled using radiomics analyses of serial imaging over the treatment course (i.e., delta-radiomics or 4-dimensional radiomics). In recent years, machine learning approaches, including deep learning, have been proposed to augment or replace current engineered radiomic features (43). These approaches could usher in new treatment paradigms (Fig. 1), in which quantitative imaging using radiomics methods allows for a more comprehensive understanding of tumor phenotype spatially and temporally.

In the last 5 years, an exponential increase in the number of radiomics publications has occurred, with a widening number of applications in many subdisciplines of radiology and radiation oncology (55, 56). The rapid development of the field has resulted in many publications containing results that are difficult, if not impossible, to reproduce, which has greatly hindered the clinical translation of actionable models. This shortcoming is based on a lack of standardization and, therefore, variable quality of the input data. On a basic level, many studies provide insufficient methodologic detail and are conducted on patient cohorts that are underpowered for statistical significance and creation of valid generalizable models. Today, there exist many sources of variability in conducting quantitative imaging research (57-59). Notably, given the heterogeneity in acquisition and reconstruction of positron emission tomography images, caution has been urged in developing quantitative imaging models using positron emission tomography (60-63). The primary aim of quantitative imaging models should be to discriminate signal amid numerous sources of noise present in the process, and underpowered studies will fail to produce reliable or robust results. Similarly, the field of genomics, in its infancy, also suffered from analyses that were nongeneralizable. At this writing, the field of quantitative imaging and radiomics in particular requires a renewed focus on optimal study design practices, standardization, meaningfulness, usefulness, data sharing, and clinical trials (56). In the coming years, international cooperative efforts will be required to quantify the added value of the most promising quantitative models compared with existing methods. Furthermore, only through carefully

designed and well-powered clinical trials will quantitative imaging demonstrate its worth.

Ensuring Quality Research

The development and clinical validation of radiomics models face many challenges in practical implementation, the foremost of which is that most current radiomics studies suffer from severe reproducibility issues. Because the workflow of radiomics prediction model development, image acquisition and reconstruction, image post-processing (including data compression), feature calculation, statistical analysis, and clinical validation (Fig. 2) is highly complex, standardization and best practice guidelines must be implemented at every step in the workflow. Feature calculation alone involves many critical processing steps, including, for example, image filtering, spatial interpolation, and intensity discretization. To address the common problem of missing information about specific procedural steps in current radiomics papers, researchers in the field recently formed the Image Biomarker Standardization Initiative (IBSI) (64). This international consortium champions 3 major goals: (1) to reach consensus and provide benchmark values for the calculation of the most commonly used radiomics features; (2) to reach consensus and provide benchmarked values for the image processing steps required before radiomics feature extraction; and (3) to provide a set of guidelines for reporting comprehensive information on radiomics experiments. Benchmark radiomics calculations have been performed on synthetic and actual sets of clinical images. Figure 2 provides an overview of the components of development and clinical implementation of radiomics models and highlights the need for comprehensive standardization of image acquisition and statistical analysis, (65, 66) similar to ongoing efforts with the IBSI.

The Transparent Reporting of a Multivariable Prediction Model for Individual Prognosis or Diagnosis (TRIPOD) Statement is a guideline specifically designed for the reporting of studies developing or validating a multivariable prediction model (65). Some of the reporting guidelines developed by the IBSI effort will likely overlap with TRIPOD because the method to develop diagnostic and prognostic models in quantitative imaging should not fundamentally differ from those in clinical medicine and because TRIPOD should become a useful reference. Overall, the standardization of radiomics methods in the community is an essential requirement for faster clinical translation, and the workflow and benchmarked values defined by the IBSI (and TRIPOD) represent a step toward the calibration of future radiomics investigations. Efforts of groups in radiation oncology should evolve in concert with the Quantitative Imaging Network (67), which is tasked with providing recommendations for multisite clinical trials. At this writing, the Quantitative Imaging Network is evaluating a range of multimodal imaging approaches; harmonization of image data collection; and analysis,

Fig. 2. Comprehensive list of steps and requirements for the development and clinical validation of new radiomics models and future clinical trials. Ongoing efforts at standardization are paramount in the following areas: (1) medical imaging acquisition and reconstruction; (2) workflow of computation of radiomics features proposed by the Image Biomarker Standardization Initiative (19); and (3) statistical analysis.

display, and clinical workflow methods across imaging platforms in order to test their performance across different cancer sites.

After feature extraction, statistical analysis and machine learning (Fig. 2) are needed to associate features with tumor aggressiveness and clinical outcomes. For construction of tumor outcome prediction models via multivariable analysis, radiomics studies valuable enough to be put on the path toward clinical translation must (1) include testing of radiomics-based models on independent and external testing sets of sufficiently large size to demonstrate efficacy or complementarity over conventional prognostic clinical metrics and (2) ensure that all imaging data, clinical information, and programming code related to a radiomics study are available online. Lambin et al (56) and Vallières et al (68) have provided additional details on the quality of radiomics studies, notably for standardization of imaging protocols and quality assurance. High-quality and transparent radiomics research is key for the growth of the field; researchers should strive to follow the “FAIR guiding principles” (69) by making all radiomics research objects findable, accessible, interoperable, and reusable, thus enabling independent validation and quality assurance of such research efforts.

Meaningfulness: Toward Interpretable Radiomics Models

The interpretation of selected features lies at the core of any workflow involving medical imaging. Radiographic

imaging features—qualitative descriptors (e.g., edema, necrosis, lesion/tumor contrast enhancement) noted through visual assessment by an expert radiologist—often have an intuitive interpretation. Quantitative formula-derived radiomics features, on the other hand, largely lack an easy description and are not readily and innately connected to an underlying biology or to the clinic. Successful clinical integration of quantitative imaging research and machine learning will require an increased focus on interpretable models. Figure 3 illustrates the gap between radiographic and radiomics models. The black-box aspect of the current radiomics paradigm increases the reluctance of clinicians to accept into clinical practice therapeutic decision-making paradigms based only on opaque quantitative features. Radiomics models should strive for more direct interpretation related to better-established radiology models of what drives a specific outcome. Deep learning approaches are expected to face similar challenges in adoption because of the large number of noninterpretable features. Addressing this issue is a topic of current investigations, and recent research has shown that a combination of radiographic (also called semantic) and radiomics features could increase the performance of tumor classification models, indicating an additive effect between the analyses (41). Nonetheless, given the common source for both feature types, it can be assumed that some overlap does exist—hence the need for contributions from both methods to best capture the tumor phenotype. Identifying associations between radiographic and radiomics features may help clarify their relationship and provide stronger links to the underlying biology. For example, Yip et al (55) found that

Fig. 3. Future radiomics work will need to reduce the gap in the interpretability of radiographic and radiomics quantitative imaging models. Radiographic features have so far shown predictive and better interpretability than pure radiomics or deep feature models. Understandability of predictive radiomics features is the key in moving the field forward.

all 9 radiologic features in their study were associated with at least 4 of 57 radiomics features.

Ultimately, meaningfulness stems from the core hypothesis that radiomics features afford added relevant data reflective of tumor pathophysiology that cannot be derived from standard radiologic interpretation alone. Features derived from radiomics analysis provide information that is correlated to genomic, cellular, and metabolic features of tumors, such as human papilloma virus status (70), isocitrate dehydrogenase mutation, estimated glomerular filtration rate (EGFR) mutations, hypoxia, necrosis, or T cell infiltration. Typically, some of these variables are continuous rather than dichotomous; therefore, a scaled descriptor, such as degree of hypoxia assessed from a radiomics signature, may be a more suitable than a simple binary endpoint. The 3 main advantages of a radiomics-based approach are the cost (cheaper than genome sequencing), its basis in information from the whole tumor (rather than a limited biopsy, which may not capture the heterogeneity present within the tumor), and the added spatial resolution (e.g., one could define the level of T cell infiltration in the primary lesion, lymph nodes and metastases). It is expected that future research will continue to bridge the gap between radiographic and radiomics features in creating more interpretable models.

Usefulness: Toward Actionable Radiomics Signatures

The clinical utility of radiomics signatures is dependent on several factors. Ultimately, useful quantitative imaging research needs to add to existing knowledge or simplify existing methods. The first step is for the radiomics models to be generalizable. External validation of the radiomics model is crucial to evaluate performance beyond the walls of the institutes in which the signature was trained. Although small, single-institution studies have value as a conceptual demonstration of methodology and in generating new hypotheses, their lack of external validation

greatly hinders broader applicability and acceptance of radiomics signatures in the clinic. Second, careful consideration must be given to the outcome that the models are attempting to predict. Radiomics signatures can be trained to predict many kinds of structured, quantifiable outcomes, but the obtained models must be actionable. Examples of prediction types are diagnostics, prognosis, treatment stratification and automated reporting (Fig. 1). The degree to which a radiomics model improves current treatment decisions is an important factor for determining usefulness. Third, the volume and specificity of the data on which the radiomics signature is trained—and subsequently validated—is essential. Access to large databases of medical images is rare, largely because of the logistical hurdles associated with data sharing in the medical field; therefore, radiomics signatures are often derived from small cohorts of patients. This shortcoming is a particular concern for exploration of deep learning methods, which often require significantly more systematically acquired patient images. Finally, the ultimate usefulness of radiomics models will come from studies that demonstrate that quantification of imaging features at the organ level can safely replace existing biomarkers and methods at the microscopic level. Bottom-up and top-down study methods (Fig. 4) will likely be the focus of quantitative imaging research efforts for years to come. Combined efforts in radiomics and genomics should increase the robustness of predictive models and further resolve meaningfulness while improving interpretability.

Once the efficacy of a given radiomics-based model has been assessed on a sufficient number of independent and external data sets from different institutions, the most important step as part of clinical translation is to test its potential benefit in influencing clinical decision-making by improving patient outcomes in randomized clinical trials. The clinical deployment of radiomics should be subject to the same rigor in development and implementation as exists with conventional novel diagnostic and therapeutic interventions, with the goal of doing no harm and establishing a clinically cost-effective and meaningful instrument. In the

Fig. 4. Biological meaningfulness of radiomics models will require deep understanding of DNA and proteins. Radiomic and genomic efforts in the coming years will likely combine via top-down and bottom-up scientific approaches. Figure modified from Parmar et al (11).

future, medical scientists with expertise in imaging analytics and data science must play a major role in the development of clinical trials to better consolidate the relevance of radiomics into routine clinical practice.

Toward Deep Learning

Conventional radiomics techniques have relied mainly on quantifying images using a finite set of human-crafted informative features (e.g., tumor morphology, tumor intensity, texture or spatial frequency information). In the general computer vision and object recognition fields, the use of texture features to quantify images can be traced back to as early as 1955 (71). Machine learning algorithms, such as random forests and gradient boosting, correlate informative features to different outcomes. Although many radiomics papers have been published using these techniques, both random forests and gradient boosting depend on the quality of the features provided. Using handcrafted or explicitly designed textures may limit prediction accuracy on image classification tasks.

Parallel to the development of the field of radiomics in radiation oncology, general computer vision has experienced a new revolution. Motivated by the early work of Yann LeCun et al, convolutional neural networks (CNNs) (72) have been developed that not only correlate features to outcomes but also design completely new sets of features. The ability of CNNs to combine high-order feature

characteristics (e.g., lines and circles) into new features to distinguish images has achieved breakthrough prediction accuracy in a variety of challenges, including the ImageNet Large Scale Visual Recognition Competition. Publically available high-level programming packages (e.g., TensorFlow, Theano, Caffe, and PyTorch) have eliminated much of the low-level computational rigor and helped to accelerate the use of deep learning algorithms applied to radiomics tasks. Applications of CNNs in radiomics applications (deep radiomics) are starting to make headway (44, 73). However, CNNs require more data than previous approaches, necessitating the incorporation of transfer learning, data augmentation, and multitask learning techniques to mitigate the amount of data required. In addition, prediction models based on deep learning can easily be subject to biases and tend to be difficult to interpret. Efforts should be made to understand the relationship among data set sizes, possible confounders, and performance of outcome prediction. Performing explicit prediction of specific biological observations (e.g., tumor necrosis, hypoxia) may be a more realistic short-term goal than trying to account for overall survival. It is anticipated that multitask learning will help to provide a degree of interpretation for deep learning approaches (74). Given enough high-quality data (text and images), it is expected that the role of CNNs will continue to expand in medicine and quantitative imaging (75-80).

New Paradigm for Data Sharing

Rapid-learning health care is a digital framework (Fig. 5) meant to drive scientific discovery and clinical implementation of decision-support systems at a faster pace. This objective depends on new paradigms of easier collaboration, with the aim of accumulating large, high-quality, well-curated data sets for appropriate analysis. In oncology, this paradigm essentially consists of unlocking and repurposing available clinical data to accelerate knowledge acquisition and form models that can predict cancer treatment outcomes, with the hypothesis that past outcome results can constantly and iteratively improve the prediction of future outcomes (81).

In this framework, external knowledge coming from clinical trials is used to optimize learning. Figure 5 summarizes key data elements that may improve the design of quantitative imaging-based data warehouse and clinical trials. Contributions from multiple cancer centers will be necessary to obtain sufficient statistical evidence that a given image-based prediction model can improve decision-making in the clinic for patient cohorts spanning a substantial spectrum of the population. Next, standardization and quality assurance of image-based methods implemented in any investigational project or clinical trial are fundamental for the long-term reproducibility of application of a given model. In addition, the use of dedicated image-based ontologies, such as the Radiomics Ontology

Fig. 5. Keys to the successful implementation of quantitative imaging data warehouse for new research and clinical trials in oncology. Orchestrated participation by multiple institutions, national boards, manufacturers, and scientific associations is necessary to achieve the best approach for unlocking trapped oncology data for quantitative data warehouses. Successful institutions will implement clinical and informatic infrastructure changes to accumulate data from electronic health records, Oncology Information System, patient outcomes, picture archives and communication systems, and other research auxiliary databases. Adoption of standardization, quality assurance, ontologies, and distributed learning methods will ensure optimal worldwide rapid health care learning.

(<https://bioportal.bioontology.org/ontologies/RO>), will facilitate the interoperability of analyses via standardized reporting and descriptions of radiomics methods. Finally, the participation of all health care actors, including government entities (e.g., the National Cancer Institute and the National Institutes of Health), professional associations (e.g., the Radiological Society of North America, the American Society for Radiation Oncology, and the American Association of Physicists in Medicine), patient advocacy groups, and industry would significantly improve the technical and practical aspects of data sharing and clinical trial designs. Such a vision will require better integration of electronic health record with oncology information systems and picture archiving and communication systems (PACS). Standardized communication formats (e.g., Fast Healthcare Interoperability Resources [<https://www.hl7.org/fhir/overview.html>]) may become the leading vehicle to share medical data and instructions between existing systems.

Increasing evidence demonstrates that high-dimensional quantitative information extracted from medical images of cancer constitutes an invaluable source of data that could be used to better decode tumor biology and support clinical decision-making. Fortunately, anatomic and physiological imaging is now acquired routinely at every step of clinical cancer management, from tumor diagnosis to tumor staging, treatment planning, treatment delivery (e.g., cone beam computed tomography) (82), treatment response monitoring and long-term follow-up. Moreover, the ability to

meticulously select, mine and combine different medical imaging components into actionable clinical models via advanced quantitative image analysis and machine learning has reached an unprecedented level. To fully harness the potential benefits of these immense sources of data and state-of-the-art techniques, but most of all for a faster translation of quantitative imaging-based decision support into the clinical environment, it is crucial that all members of the medical imaging community act together to create worldwide consortiums, with the aim to improve practices, standardization, meaningfulness, usefulness, data sharing and clinical trial designs. A tangible first step could be to fully incorporate simple metrics, such as tumor size and shape in the temporal management of cancer, whenever adequate. It will only be then that we will begin to realize the full potential of medical imaging and observe more rapid translation of quantitative imaging-based models into routine clinical practice.

References

1. Segal E, Sirlin CB, Ooi C, et al. Decoding global gene expression programs in liver cancer by noninvasive imaging. *Nat Biotechnol* 2007;25:675-680.
2. El Naqa I, Grigsby P, Apte A, et al. Exploring feature-based approaches in PET images for predicting cancer treatment outcomes. *Pattern Recognit* 2009;42:1162-1171.
3. Lambin P, Rios-Velazquez E, Leijenaar R, et al. Radiomics: Extracting more information from medical images using advanced feature analysis. *Eur J Cancer* 2012;48:441-446.

4. Aerts HJWL, Velazquez ER, Leijenaar RTH, et al. Decoding tumour phenotype by noninvasive imaging using a quantitative radiomics approach. *Nat Commun* 2014;5:4006.
5. Gillies RJ, Anderson AR, Gatenby RA, et al. The biology underlying molecular imaging in oncology: From genome to anatomy and back again. *Clin Radiol* 2010;65:517-521.
6. Gillies RJ, Kinahan PE, Hricak H. Radiomics: Images are more than pictures, they are data. *Radiology* 2016;278:563-577.
7. Hara JH, Wu A, Villanueva-Meyer JE, et al. Clinical applications of quantitative 3-dimensional MRI analysis for pediatric embryonal brain tumors. *Int J Radiat Oncol Biol Phys* 2018;102:744-756.
8. Vallières M, Kay-Rivest E, Perrin LJ, et al. Radiomics strategies for risk assessment of tumour failure in head-and-neck cancer. *Sci Rep* 2017;7:10117.
9. Parmar C, Leijenaar RTH, Grossmann P, et al. Radiomic feature clusters and prognostic signatures specific for lung and head & neck cancer. *Sci Rep* 2015;5:11044.
10. Leijenaar RT, Carvalho S, Hoebbers FJ, et al. External validation of a prognostic CT-based radiomic signature in oropharyngeal squamous cell carcinoma. *Acta Oncol* 2015;54:1423-1429.
11. Parmar C, Grossmann P, Rietveld D, et al. Radiomic machine-learning classifiers for prognostic biomarkers of head and neck cancer. *Front Oncol* 2015;5:272.
12. Elhalawani H, Kanwar A, Mohamed ASR, et al. Investigation of radiomic signatures for local recurrence using primary tumor texture analysis in oropharyngeal head and neck cancer patients. *Sci Rep* 2018;8:1524.
13. Jethanandani A, Lin TA, Volpe S, et al. Exploring applications of radiomics in magnetic resonance imaging of head and neck cancer: A systematic review. *Front Oncol* 2018;8:131.
14. Coroller TP, Grossmann P, Hou Y, et al. CT-based radiomic signature predicts distant metastasis in lung adenocarcinoma. *Radiother Oncol* 2015;114:345-350.
15. Cunliffe A, Armato SG 3rd, Castillo R, et al. Lung texture in serial thoracic computed tomography scans: Correlation of radiomics-based features with radiation therapy dose and radiation pneumonitis development. *Int J Radiat Oncol Biol Phys* 2015;91:1048-1056.
16. Mattonen SA, Palma DA, Johnson C, et al. Detection of local cancer recurrence after stereotactic ablative radiation therapy for lung cancer: Physician performance versus radiomic assessment. *Int J Radiat Oncol Biol Phys* 2016;94:1121-1128.
17. Fave X, Zhang L, Yang J, et al. Delta-radiomics features for the prediction of patient outcomes in non-small cell lung cancer. *Sci Rep* 2017;7:588.
18. Tseng HH, Luo Y, Cui S, et al. Deep reinforcement learning for automated radiation adaptation in lung cancer. *Med Phys* 2017;44:6690-6705.
19. Guo W, Li H, Zhu Y, et al. Prediction of clinical phenotypes in invasive breast carcinomas from the integration of radiomics and genomics data. *J Med Imaging (Bellingham)* 2015;2:041007.
20. Wang J, Kato F, Oyama-Manabe N, et al. Identifying triple-negative breast cancer using background parenchymal enhancement heterogeneity on dynamic contrast-enhanced MRI: A pilot radiomics study. *PLoS One* 2015;10:e0143308.
21. Li H, Zhu Y, Burnside ES, et al. MR imaging radiomics signatures for predicting the risk of breast cancer recurrence as given by research versions of mammprint, oncotype DX, and PAM50 gene assays. *Radiology* 2016;281:382-391.
22. Li H, Zhu Y, Burnside ES, et al. Quantitative MRI radiomics in the prediction of molecular classifications of breast cancer subtypes in the TCGA/TCIA data set. *NPJ Breast Cancer* 2016;2.
23. Sutton EJ, Huang EP, Drukker K, et al. Breast MRI radiomics: Comparison of computer- and human-extracted imaging phenotypes. *Eur Radiol Exp* 2017;1:22.
24. Zhang Q, Xiao Y, Suo J, et al. Sonoelastomics for breast tumor classification: A radiomics approach with clustering-based feature selection on sonoelastography. *Ultrasound Med Biol* 2017;43:1058-1069.
25. Dong Y, Feng Q, Yang W, et al. Preoperative prediction of sentinel lymph node metastasis in breast cancer based on radiomics of T2-weighted fat-suppression and diffusion-weighted MRI. *Eur Radiol* 2018;28:582-591.
26. Drukker K, Li H, Antropova N, et al. Most-enhancing tumor volume by MRI radiomics predicts recurrence-free survival "early on" in neoadjuvant treatment of breast cancer. *Cancer Imaging* 2018;18:12.
27. Guo Y, Hu Y, Qiao M, et al. Radiomics analysis on ultrasound for prediction of biologic behavior in breast invasive ductal carcinoma. *Clin Breast Cancer* 2018;18:e335-e344.
28. Whitney HM, Taylor NS, Drukker K, et al. Additive benefit of radiomics over size alone in the distinction between benign lesions and luminal a cancers on a large clinical breast MRI dataset [e-pub ahead of print]. *Acad Radiol* 2018. <https://doi.org/10.1016/j.acra.2018.04.019>. Accessed April 15, 2018.
29. Zhou Y, Xu J, Liu Q, et al. A radiomics approach with CNN for shear-wave elastography breast tumor classification. *IEEE Trans Biomed Eng* 2018;65:1935-1942.
30. Cozzi L, Dinapoli N, Fogliata A, et al. Radiomics based analysis to predict local control and survival in hepatocellular carcinoma patients treated with volumetric modulated arc therapy. *BMC Cancer* 2017;17:829.
31. Perrin T, Midya A, Yamashita R, et al. Short-term reproducibility of radiomic features in liver parenchyma and liver malignancies on contrast-enhanced CT imaging. *Abdom Radiol (NY)* 2018. <https://doi.org/10.1007/s00261-018-1600-6>. Accessed April 15, 2018.
32. Leseur J, Roman-Jimenez G, Devillers A, et al. Pre- and per-treatment 18F-FDG PET/CT parameters to predict recurrence and survival in cervical cancer. *Radiother Oncol* 2016;120:512-518.
33. Reuze S, Orlhac F, Chargari C, et al. Prediction of cervical cancer recurrence using textural features extracted from 18F-FDG PET images acquired with different scanners. *Oncotarget* 2017;8:43169-43179.
34. Lucia F, Visvikis D, Desseroit MC, et al. Prediction of outcome using pretreatment (18)F-FDG PET/CT and MRI radiomics in locally advanced cervical cancer treated with chemoradiotherapy. *Eur J Nucl Med Mol Imaging* 2018;45:768-786.
35. Liu Y, Zhang Y, Cheng R, et al. Radiomics analysis of apparent diffusion coefficient in cervical cancer: A preliminary study on histological grade evaluation [e-pub ahead of print]. *J Magn Reson Imaging* 2018. <https://doi.org/10.1002/jmri.26192>. Accessed April 15, 2018.
36. Bowen SR, Yuh WTC, Hippe DS, et al. Tumor radiomic heterogeneity: Multiparametric functional imaging to characterize variability and predict response following cervical cancer radiation therapy. *J Magn Reson Imaging* 2018;47:1388-1396.
37. Gnep K, Fargeas A, Gutierrez-Carvajal RE, et al. Haralick textural features on T2-weighted MRI are associated with biochemical recurrence following radiotherapy for peripheral zone prostate cancer. *J Magn Reson Imaging* 2017;45:103-117.
38. Shiradkar R, Ghose S, Jambor I, et al. Radiomic features from pretreatment biparametric MRI predict prostate cancer biochemical recurrence: Preliminary findings [e-pub ahead of print]. *J Magn Reson Imaging* 2018. <https://doi.org/10.1002/jmri.26178>. Accessed April 15, 2018.
39. Vallières M, Freeman CR, Skamene SR, et al. A radiomics model from joint fdg-pet and MRI texture features for the prediction of lung metastases in soft-tissue sarcomas of the extremities. *Phys Med Biol* 2015;60:5471-5496.
40. Vallières M, Laberge S, Diamant A, et al. Enhancement of multi-modality texture-based prediction models via optimization of PET and MR image acquisition protocols: A proof of concept. *Phys Med Biol* 2017;62:8536-8565.
41. Coroller TP, Bi WL, Huynh E, et al. Radiographic prediction of meningioma grade by semantic and radiomic features. *PLoS One* 2017;12:e0187908.

42. Katsila T, Matsoukas MT, Patrinos GP, et al. Pharmacometabolomics informs quantitative radiomics for glioblastoma diagnostic innovation. *OMICS* 2017;21:429-439.
43. Lao J, Chen Y, Li ZC, et al. A deep learning-based radiomics model for prediction of survival in glioblastoma multiforme. *Sci Rep* 2017;7:10353.
44. Li Z, Wang Y, Yu J, et al. Deep learning based radiomics (DLR) and its usage in noninvasive IDH1 prediction for low grade glioma. *Sci Rep* 2017;7:5467.
45. Lopez CJ, Nagornaya N, Parra NA, et al. Association of radiomics and metabolic tumor volumes in radiation treatment of glioblastoma multiforme. *Int J Radiat Oncol Biol Phys* 2017;97:586-595.
46. Prasanna P, Patel J, Partovi S, et al. Radiomic features from the peritumoral brain parenchyma on treatment-naïve multi-parametric MR imaging predict long versus short-term survival in glioblastoma multiforme: Preliminary findings. *Eur Radiol* 2017;27:4188-4197.
47. Zhou H, Vallières M, Bai HX, et al. MRI features predict survival and molecular markers in diffuse lower-grade gliomas. *Neuro Oncol* 2017;19:862-870.
48. Chang K, Bai HX, Zhou H, et al. Residual convolutional neural network for the determination of IDH status in low- and high-grade gliomas from MR imaging. *Clin Cancer Res* 2018;24:1073-1081.
49. Kim JY, Park JE, Jo Y, et al. Incorporating diffusion- and perfusion-weighted MRI into a radiomics model improves diagnostic performance for pseudoprogression in glioblastoma patients [e-pub ahead of print]. *Neuro Oncol* 2018. <https://doi.org/10.1093/neuonc/noy133>. Accessed April 15, 2018.
50. Kong DS, Kim J, Ryu G, et al. Quantitative radiomic profiling of glioblastoma represents transcriptomic expression. *Oncotarget* 2018;9:6336-6345.
51. Li ZC, Bai H, Sun Q, et al. Multiregional radiomics features from multiparametric MRI for prediction of mgmt methylation status in glioblastoma multiforme: A multicentre study. *Eur Radiol* 2018;28:3640-3650.
52. Soike MH, McTyre ER, Shah N, et al. Glioblastoma radiomics: Can genomic and molecular characteristics correlate with imaging response patterns? *Neuroradiology* 2018;60:1043-1051.
53. Suh HB, Choi YS, Bae S, et al. Primary central nervous system lymphoma and atypical glioblastoma: Differentiation using radiomics approach. *Eur Radiol* 2018;28:3832-3839.
54. Xi YB, Guo F, Xu ZL, et al. Radiomics signature: A potential biomarker for the prediction of MGMT promoter methylation in glioblastoma. *J Magn Reson Imaging* 2018;47:1380-1387.
55. Yip SS, Aerts HJ. Applications and limitations of radiomics. *Phys Med Biol* 2016;61:R150-R166.
56. Lambin P, Leijenaar RTH, Deist TM, et al. Radiomics: The bridge between medical imaging and personalized medicine. *Nat Rev Clin Oncol* 2017;14:749-762.
57. Zhao B, James LP, Moskowitz CS, et al. Evaluating variability in tumor measurements from same-day repeat CT scans of patients with non-small cell lung cancer. *Radiology* 2009;252:263-272.
58. Mackin D, Fave X, Zhang L, et al. Measuring computed tomography scanner variability of radiomics features. *Invest Radiol* 2015;50:757-765.
59. Zhao B, Tan Y, Tsai WY, et al. Reproducibility of radiomics for deciphering tumor phenotype with imaging. *Sci Rep* 2016;6:23428.
60. Tixier F, Le Rest CC, Hatt M, et al. Intratumor heterogeneity characterized by textural features on baseline 18F-FDG PET images predicts response to concomitant radiochemotherapy in esophageal cancer. *J Nucl Med* 2011;52:369-378.
61. Hatt M, Tixier F, Cheze Le Rest C, et al. Robustness of intratumour (1)(8)F-FDG PET uptake heterogeneity quantification for therapy response prediction in oesophageal carcinoma. *Eur J Nucl Med Mol Imaging* 2013;40:1662-1671.
62. Hatt M, Tixier F, Pierce L, et al. Characterization of pet/ct images using texture analysis: The past, the present... Any future? *Eur J Nucl Med Mol Imaging* 2017;44:151-165.
63. Leijenaar RT, Nalbantov G, Carvalho S, et al. The effect of SUV discretization in quantitative FDG-PET radiomics: The need for standardized methodology in tumor texture analysis. *Sci Rep* 2015;5:11075.
64. Zwanenburg A, Leger S, Vallières M, et al. Image Biomarker Standardisation Initiative. Available at: <https://arxiv.org/abs/1612.07003>. Accessed April 15, 2018.
65. Collins GS, Reitsma JB, Altman DG, et al. Transparent reporting of a multivariable prediction model for individual prognosis or diagnosis (TRIPOD): The TRIPOD statement. *Ann Intern Med* 2015;162:55-63.
66. Deist TM, Dankers F, Valdes G, et al. Machine learning algorithms for outcome prediction in (chemo)radiotherapy: An empirical comparison of classifiers. *Med Phys* 2018;45:3449-3459.
67. Nordstrom RJ. The quantitative imaging network in precision medicine. *Tomography* 2016;2:239-241.
68. Vallières M, Zwanenburg A, Badic B, et al. Responsible radiomics research for faster clinical translation. *J Nucl Med* 2018;59:189-193.
69. Wilkinson MD, Dumontier M, Aalbersberg IJ, et al. The fair guiding principles for scientific data management and stewardship. *Sci Data* 2016;3:160018.
70. Leijenaar RT, Bogowicz M, Jochems A, et al. Development and validation of a radiomic signature to predict HPV (p16) status from standard CT imaging: A multicenter study. *Br J Radiol* 2018;91:20170498.
71. Kaizer H. A Quantification of Textures on Aerial Photographs. Boston University Research Laboratories; 1955. Technical Note 121, AD 69484.
72. Lecun Y, Boser B, Denker J, et al. Handwritten digit recognition with a back-propagation network. In: Touretzky DS, editor. *Advances in Neural Information Processing Systems 2 (NIPS 1989)*. Available at: <https://papers.nips.cc/paper/293-handwritten-digit-recognition-with-a-back-propagation-network>. Accessed April 15, 2018.
73. Paul R, Hawkins SH, Schabath MB, et al. Predicting malignant nodules by fusing deep features with classical radiomics features. *J Med Imaging (Bellingham)* 2018;5:011021.
74. Yuan H, Paskov I, Paskov H, et al. Multitask learning improves prediction of cancer drug sensitivity. *Sci Rep* 2016;6:31619.
75. Chen MC, Ball RL, Yang L, et al. Deep learning to classify radiology free-text reports. *Radiology* 2018;286:845-852.
76. Erickson BJ, Korfiatis P, Kline TL, et al. Deep learning in radiology: Does one size fit all? *J Am Coll Radiol* 2018;15:521-526.
77. Lugo-Fagundo C, Vogelstein B, Yuille A, et al. Deep learning in radiology: Now the real work begins. *J Am Coll Radiol* 2018;15:364-367.
78. McBee MP, Awan OA, Colucci AT, et al. Deep learning in radiology. *Acad Radiol* 2018. in press.
79. Summers RM. Deep learning lends a hand to pediatric radiology. *Radiology* 2018;287:323-325.
80. Yasaka K, Akai H, Kunimatsu A, et al. Deep learning with convolutional neural network in radiology. *Jpn J Radiol* 2018;36:257-272.
81. Lambin P, Zindler J, Vanneste BG, et al. Decision support systems for personalized and participative radiation oncology. *Adv Drug Deliv Rev* 2017;109:131-153.
82. van Timmeren JE, Leijenaar RTH, van Elmpt W, et al. Survival prediction of non-small cell lung cancer patients using radiomics analyses of cone-beam CT images. *Radiother Oncol* 2017;123:363-369.